Structure-Guided Design and Biophysical Characterization of Novel Anti-HIV Reagents

Despite over 30 years of effort, an HIV-1 vaccine that elicits protective antibodies still does not exist. Recent clinical studies have identified that during natural infection about 20% of the population is capable of mounting a potent and protective antibody response. Closer inspection of these individuals reveal that a subset of these antibodies, recently termed potent VRC01-like (PVL), derive exclusively from a single human germline heavy chain gene. Induced clonal expansion of the B cell encoding this gene is the first step through which PVL antibodies may be elicited. Unfortunately, naturally occurring HIV gp120s fail to bind to this germline, and as a result cannot be used as the initial prime for a vaccine regimen. We have determined the crystal structure of an important germline antibody that is a promising target for vaccine design efforts, and have set out to engineer a more likely candidate using computationally-guided rational design.

In addition to prevention efforts on the side of vaccine design, recently characterized broadly neutralizing anti-HIV antibodies have excellent potential for use in gene therapy and passive immunotherapy. The separation distance between functional Fabs on an antibody is important due to the sparse distribution of envelop spikes on HIV compared to other viruses. We set out to build and characterize novel antibody architectures by incorporating structured linkers into the hinge region of an anti-HIV antibody b12. The goal was to observe whether these linkers increased the arm-span of the IgG dimer. When incorporated, flexible Gly4Ser repeats did not result in detectable extensions of the IgG antigen binding domains, by contrast to linkers including more rigid domains such as β2-microglobulin, Zn-α2-glycoprotein, and tetratricopeptide repeats (TPRs). This study adds an additional set of linkers with varying lengths and rigidities to the available linker repertoire, which may be useful for the modification and construction of antibodies and other fusion proteins.

Structural Characterizations of the Dimeric Anti-HIV Antibody 2G12 and the HIV-2 Envelope Glycoprotein

More than thirty years after the discovery that Human Immunodeficiency Virus (HIV) was the causative agent of Acquired Immunodeficiency Syndrome (AIDS), the disease remains pandemic as long as no effective universal vaccine is found. Over 34 million individuals in the world are infected with the virus, and the vast majority of them have no access to the antiretroviral therapies that have largely reduced HIV to a chronic disease in the developed world. The first chapter of this thesis introduces the history of the virus. The key to the infectious mechanism of the virus lies in its envelope glycoprotein (Env), a trimeric spike on the viral surface that utilizes host T cell receptors for entry. Though HIV-1 Env is immunogenic, most infected patients do not mount an effective neutralizing antibody response against it. Broadly-neutralizing anti-Env antibodies (bNAbs) present in the serum of a minority of infected individuals are usually sufficient to prevent the progression to full blown AIDS. Thus, the molecular details of these bNAbs as well as the antibody-antigen interface are of prime interest for structural studies, as insight gained would contribute to the design of a more effective immunogen and potential vaccine candidate. The second chapter of this thesis describes the low-resolution crystal structure of one such antibody, 2G12 dimer, which targets a high mannose epitope on the surface of Env. Patients infected with HIV-2, a related virus with ~35% sequence identity in the Env region, can generally mount a robust antibody response sufficient for viral control for reasons still unknown. The final two chapters of this thesis focus on the first reported structural studies of HIV-2 Env, the molecular details of which may inform HIV-1 therapy and immunogen design.

O diagnóstico anti-HIV no município do Rio de Janeiro: processos dos cuidados em saúde.

A magnitude e as modificações resultantes da epidemia de Aids no Brasil levaram o Ministério da Saúde a recomendar, a partir de 2001, a incorporação do diagnóstico sorológico da infecção pelo HIV em serviços de atenção básica da rede pública de saúde, visando a universalidade e a ampliação do acesso da população a esses exames. O processo diagnóstico, no caso da AIDS, envolve para além da simples disponibilização da testagem; cobre demandas de prevenção, profilaxia, tratamento e referências adequadas para o interior do sistema assistencial. O estudo realizado teve por objetivo investigar como vem se dando a oferta deste diagnóstico, previsto de estar acontecendo acompanhado de aconselhamento pré e pós-teste, usando como lócus um conjunto de serviços da rede básica de saúde no Município do Rio de Janeiro. Do tipo descritivo-analítico, o trabalho utilizou-se de uma abordagem metodológica qualitativa, realizando entrevistas semi-estruturadas com vinte e dois profissionais de saúde de diversas categorias, envolvidos nos processos de testagem anti-HIV, e com três gestores, buscando compreender como vem sendo ofertado esse cuidado em saúde. O exame do material obtido permitiu a identificação das seguintes categorias analíticas: oferta do teste na rede de atenção básica e dilemas relacionados a esse processo; ações de aconselhamento que acompanham a testagem; resultados do teste anti-HIV e dificuldades na sua comunicação aos usuários; dimensões estrutural e organizacional e gestão do processo de testagem; capacitação dos recursos humanos. Identificou-se que o processo de oferta do teste anti-HIV se circunscreve frequentemente à representação da doença e é necessária maior interlocução na relação profissional de saúde/usuário, considerando a intersubjetividade dos sujeitos envolvidos. Este processo diagnóstico demanda técnicas como apoio, acolhimento e escuta qualificada das necessidades de saúde, entendidas para além das queixas biológicas dos sujeitos, que nem sempre estão se fazendo presentes nos serviços de atenção investigados. Como desafio premente na oferta do diagnóstico anti-HIV, destaca-se que o aconselhamento deve ser uma ferramenta utilizada e reforçada no contexto dos serviços de saúde que atendem pacientes com DST/Aids. Outro desafio, além da capacitação qualificada dos recursos humanos envolvidos, é necessidade de permanente avaliação do processo de oferta que vem sendo oferecido nos serviços da rede básica, que possibilite repensar as atividades de prevenção, o acolhimento e a escuta, e o compartilhamento de idéias entre profissionais que atuam no cotidiano das unidades de saúde e os gestores locais. A pluralidade de questões no fazer em saúde exige que os serviços de saúde e seus responsáveis promovam novos arranjos para que a oferta do teste anti-HIV, como ação de saúde, seja realizada com base na humanização, na integralidade e no respeito aos direitos de cidadania, contribuindo para que a melhoria do atendimento na rede básica se concretize com qualidade.

Ensaios clínicos com vcinas anti-HIV/AIDS:a rotina de incorporação de uma prática científica

O estudo acompanha a rotina de um ensaio clínico de vacinas experimentais anti-HIV/AIDS desenvolvido no Projeto Praça Onze, da UFRJ, em colaboração com a rede mundial de pesquisas de vacinas anti-HIV/AIDS, HVTN (HIV Vaccine Trials Network) e apoio financeiro dos NIH (National Institutes of Health), dos EUA. Focaliza os processos de recrutamento, seleção e seguimento dos voluntários, articulando os aspectos mais gerais às particularidades e demandas locais deste estudo realizado no Rio de Janeiro, Brasil. Do ponto de vista teórico-conceitual utiliza recursos oriundos das ciências sociais - história, sociologia da ciência e da corrente interacionista da sociologia. O estudo mostra que, como todo ensaio clínico, o experimento do Projeto Praça Onze é uma atividade coletiva, sustentada sobre múltiplos atores e instâncias, com diversas racionalidades, o que gera uma permanente tensão. Estuda a tensão que se coloca, principalmente entre a expectativa dos profissionais envolvidos (aconselhadores, recrutadores, médicos, enfermeiros, farmacêuticos, gerentes e coordenadores de estudos) e a experiência vivenciada pelos voluntários, assim como as possíveis negociações propostas durante o desenvolvimento do protocolo, a partir do contexto sociopolítico onde o mesmo está inserido. Os profissionais, apesar de suas especificidades, articulam-se para incorporar do universo dos colegas suas linguagens e seus modos de agir, num processo de hibridização dos conhecimentos e práticas. Os voluntários do ensaio, por sua vez, submetem-se, por um lado a uma rotina de disciplina e compromisso, que implica na entrega de seu corpo à medicina, implícita nesse papel. Por outro, apropriam-se da lógica do ensaio clínico para, em sua ótica, transformar-se em um coadjuvante no descobrimento de uma nova biotecnologia, que neste caso, se coloca como uma questão de vida ou morte, para ele e para uma ampla comunidade de infectados pelo HIV. Para o voluntário a entrega do corpo à ciência faz parte da construção de uma bioidentidade e de uma biopolítica contemporânea, onde não se pode desconsiderar a constante inter-relação entre ciência, sociedade, técnica e política.

Molecular characterization of Trimeresurus stejnegeri venom L-amino acid oxidase with potential anti-HIV activity

A novel L-amino acid oxidase, named TSV-LAO, has been purified and cloned from the snake Trimeresurus stejnegeri. Fifty percentage cytotoxic concentrations (CC50) of TSV-LAO on C8166 cells were 24 and 390 nM in the absence or presence of catalase (400nM), respectively. However, at concentrations that showed little effect on cell viability, TSV-LAO displayed dose dependent inhibition on HIV-1 infection and replication. The antiviral selectivity indexes (CC50/EC50) were 16 and 6, respectively, corresponding to the measurements of syncytium formation and HIV-1 p24 antigen expression. Interestingly, the presence of catalase resulted in an increase of its antiviral selectivity to 52 and 38. Under the same conditions, no anti-HIV-1 activity was observed by exogenous addition of H2O2. The complete amino acid sequence of TSV-LAO, as deduced from its cDNA, exhibits a high degree of sequence identity with other snake venom LAOs. (C) 2003 Elsevier Inc. All rights reserved.

A novel heme-containing protein with anti-HIV-1 activity from skin secretions of Bufo andrewsi

A novel protein, named BAS-AH, was purified and characterized from the skin of the toad Bufo andrewsi. BAS-AH is a single chain protein and the apparent molecular weight is about 63 kDa as judged by SDS-PAGE. BAS-AH was determined to bind heme (0.89 mol heme/mol protein) as determined by pyridine haemochrome analysis. Fifty percentage cytotoxic concentration (CC50) of BAS-AH on C8166 cells was 9.5 mu M. However, at concentrations that showed little effect oil cell viability, BAS-AH displayed dose dependent inhibition oil HIV-1 infection and replication. The antiviral selectivity indexes corresponding to the measurements of syncytium formation and HIV-1 p24 (CC50/EC50) were 14.4 and 11.4, respectively, corresponding to the . BAS-AH also showed an inhibitory effect on the activity of recombinant HIV-1 reverse transcriptase (IC50 = 1.32 mu M). The N-terminal sequence of BAS-AH was determined to be NAKXKADVIGKISILLGQDNLSNIVAM, which exhibited little identity with other known anti-HIV-1 proteins. BAS-AH is devoid of antibacterial, protcolytic, trypsin inhibitory activity, (L)-amino acid oxidase activity and catalase activity. (c) 2005 Elsevier Ltd. All rights reserved.

A new anti-HIV lupane acid from Gleditsia sinensis Lam.

A new lupane acid, 2 beta-carboxyl, 3 beta-hydroxyl-norlupA (1)-20 (29)-en-28-oic acid (1), together with five known lupane acid derivatives (2-6), were isolated from the stings of Gleditsia sinensis Lam.. Their structures were elucidated on the basis of

法落海的化学成分及抗HIV活性

下载PDF阅读器利用多种柱层析方法,从法落海(Angelica apaensis)95%乙醇提取物中分离得到8个化合物.经IR、MS、NMR等波谱数据鉴定为氧化前胡素(oxypeucedanin,1)、氧化前胡素水合物(oxypeucedanin hydrate,2)、异欧芹属乙素(isoimperatorin,3)、白当归脑(byakangelicin,4)、白当归素(byakangelicol,5)、3'-O-acetylhamaudol (6)、(+)-9(Z),17-octadecadiene-12,14-diyne-1,11,16-triol(7)和9,17-octadecadiene-12,14-diyne-1,11,16-triol,1-acetate(8),其中,化合物6-8是首次从该植物中分离得到.我们对所有得到的8个化合物进行抗HIV活性分析,化合物1具有明显的抗HIV活性,其抑制合胞体形成的半数有效浓度(EC50)为1.6 ms/L,治疗指数(TI)为17.59.

Anti-HIV-1 activity of trichobitacin, a novel ribosome-inactivating protein

AIM: To determine whether trichobitacin, a novel ribosome-inactivating protein purified from the root tubers of Trichosanthes kirilowii, possesses the anti-HIV activity. METHODS: The inhibition of syncytial cell formation induced by human immunodeficiency virus type 1 (HIV-1),was determined under microscope, reduction of HIV-1 p24 antigen expression level was measured by ELISA, and decrease in numbers of HIV-1 antigen positive cells in acutely and-chronically infected cultures were detected by indirect immunofluorescence assay. RESULTS: Trichobitacin Was-found to greatly suppress syncytial cell formation induced by HIV-1 and to markedly reduce both expression of HIV-1 p24 antigen and the number of HIV antigen positive cells in acutely but not chronically HIV-1 infected culture. The median inhibitory concentration (IC50) in inhibition of syncytial cell formation and HIV antigen positive cells were 5 mu g.L-1 (95 % confidence limits: 1.3 - 20 mu g.L-1) and 0.09 mg.L-1 (95 % confidence limits: 0.011 - 0.755 mg.L-1), respectively. CONCLUSION: Trichobitacin is a novel ribosome-inactivating protein with anti-HIV-l activity.

Xanthohumol, a novel anti-HIV-1 agent purified from Hops Humulus lupulus

Xanthohumol, prenylchacone flavonoid, is a natural product with multi-biofunctions purified from Hops Humulus lupulus. Its anti-HIV-1 activity was tested in the present study. Results showed that xanthohumol inhibited HIV-1 induced cytopathic effects, the production of viral p24 antigen and reverse transcriptase in C8166 lymphocytes at non-cytotoxic concentration. The EC50 values were 0.82, 1.28 and 0.50 mug/ml, respectively. The therapeutic index (TI) was about 10.8. Xanthohumol also inhibited HIV-1 replication in PBMC with EC50 value of 20.74 mug/ml. The activity of recombinant HIV-1 reverse transcriptase and the HIV-1 entry were not inhibited by xanthohumol. The results from this study suggested that xanthohumol is effective against HIV-1 and might serve as an interesting lead compound. It may represent a novel chemotherapeutic agent for HIV-1 infection. However, the mechanism of its anti-HIV-1 effect needs to be further clarified. (C) 2004 Elsevier B.V. All rights reserved.

Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduced potency in vitro

Trichosanthin (TCS) was the first ribosome inactivating protein found to possess anti-HIV-1 activity. Phase I/II clinical trial of this compound had been done. Antigenicity and short plasma half-life were the major side effects preventing further clinical trial. Modification of TCS is therefore necessary to revive the interest to develop this compound as an anti-HIV agent. Three potential antigenic sites (Ser-7, Lys-173, and Gln-219) were identified by computer modeling. Through site-directed mutagenesis, these three antigenic amino acids were mutated to a cysteine residue resulting in 3 TCS mutants, namely S7C, K173C, and Q219C. These mutants were further coupled to polyethylene glycol with a molecular size of 20 kDa (PEG) via the cysteine residue. This produced another three TCS derivatives, namely PEG(20)k-S7C, PEG(20)k-K173C, and PEG(20)k-Q219C. PEGylation had been widely used recently to decrease immunogenicity by masking the antigenic sites and prolong plasma half-life by expanding the molecular size. The in vitro anti-HIV-1 activity of these mutants and derivatives was tested. Results showed that the anti-HIV-1 activity of S7C, K173C, and Q219C was decreased by about 1.5- to 5.5-fold with slightly lower cytotoxicity. On the other hand, PEGylation produced larger decrease (20- to 30-fold) in anti-HIV activity. Cytotoxicity was, however, weakened only slightly by about 3-fold. The in vitro study showed that the anti-HIV activity of PEGylated TCS was retained with reduced potency. The in vivo activity is expected to have only slightly changed due to other beneficial effects like prolonged half-life. (C) 2004 Elsevier Inc. All rights reserved.

Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro

Aim: To study the pharmacokinetics of sifuvirtide, a novel anti-human immunodeficiency virus (HIV) peptide, in monkeys and to compare the inhibitory concentrations of sifuvirtide and enfuvirtide on HIV-1-infected-cell fusion. Methods: Monkeys received 1.2 mg/kg iv or sc of sifuvirtide. An on-line solid-phase extraction procedure combined with liquid chromatography tandem mass spectrometry (SPELC/MS/MS) was established and applied to determine the concentration of sifuvirtide in monkey plasma. A four-I-127 iodinated peptide was used as an internal standard. Fifty percent inhibitory concentration (IC50) of sifuvirtide on cell fusion was determined by co-cultivation assay. Results: The assay was validated with good precision and accuracy. The calibration curve for sifuvirtide in plasma was linear over a range of 4.88-5000 mu g/L, with correlation coefficients above 0.9923. After iv or sc administration, the observed peak concentrations of sifuvirtide were 10626 +/- 2886 mu g/L and 528 +/- 191 mu g/L, and the terminal elimination half-lives (T,12) were 6.3 +/- 0.9 h and 5.5 +/- 1.0 h, respectively. After sc, T-max was 0.25-2 h, and the absolute bioavailability was 49% +/- 13%. Sifuvirtide inhibited the syncytium formation between HIV-1 chronically infected cells and uninfected cells with an IC50 of 0.33 mu g/L. Conclusion: An on-line SPE-LC/MS/MS approach was established for peptide pharmacokinetic studies. Sifuvirtide was rapidly absorbed subcutaneously into the blood circulation. The T-1/2 of sifuvirtide was remarkably longer than that of its analog, enfuvirtide, reported in healthy monkeys and it conferred a long-term plasma concentration level which was higher than its IC50 in vitro.

Structure and anti-HIV activity of micrandilactones B and C, new nortriterpenoids possessing a unique skeleton from Schisandra micrantha

Two new highly oxygenated nortriterpenoids with a unique norcycloartane skeleton, micrandilactones B and C (1-2), were isolated from Schisandra micrantha; micrandilactone C ( 2) exhibited an EC50 value of 7.71 mu g/mL (SI > 25.94) against HIV-1 replication with minimal cytotoxicity, and the potent anti-HIV-1 activity and unique structural features of 2 make it a promising lead for therapeutic development of a new generation of anti-HIV drug.

Lancifodilactone G: A unique nortriterpenoid isolated from Schisandra lancifolia and its anti-HIV activity

Lancifodilactone G (1), a novel, highly oxygenated nortriterpenoid featuring a partial enol structure and a spirocyclic moiety, was isolated from the medicinal plant Schisandra lancifolia. Its structure and stereochemistry were determined from extensive one- and two-dimensional NMR and mass spectral data, coupled with single-crystal X-ray analysis. Compound 1 exerted minimal cytotoxicity against C8166 cells (CC50 > 200 mu g/mL) and showed anti-HIV activity with EC50 = 95.47 +/- 14.19 mu g/mL and a selectivity index in the range of 1.82-2.46.